Selective Estrogen Receptor Degraders (SERDs): A Promising Strategy for Estrogen Receptor Positive Endocrine-Resistant Breast Cancer

Molecular portraits of human breast tumours

Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551

The nuclear receptor superfamily: the second decade

Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964

Molecular basis of agonism and antagonism in the oestrogen receptor

Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M. (1997) · Nature · doi:10.1038/39645 · Cited by 3,355

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer

Prat, A., Parker, J. S., Karginova, O. A., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,290

Metastatic Behavior of Breast Cancer Subtypes

Kennecke, H., Yerushalmi, R., Woods, R., Cheang, M. C. U., Voduc, D., Speers, C. H., Nielsen, T. O., & Gelmon, K. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9820 · Cited by 2,262

Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase

Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964

Nuclear Receptor Coregulators: Cellular and Molecular Biology

McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,941

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

† (2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,550

Tamoxifen in the Treatment of Breast Cancer

Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,327

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

Toy, W., Shen, Y., Won, H. H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K. P., Fanning, S. W., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,280

Biological determinants of endocrine resistance in breast cancer

Musgrove, E. A., & Sutherland, R. L. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2713 · Cited by 1,274

The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer

Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,240

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou, J., Massarweh, S., Osborne, C., Wakeling, A., Ali, S., Weiss, H., & Schiff, R. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,236

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145

Untitled work

(1991) · PubMed · Cited by 1,101

Estrogen receptor pathways to AP-1.

Kushner, P., Agard, D., Greene, G., Scanlan, T., Shiau, A., Uht, R., & Webb, P. (2000) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 953

Overcoming Endocrine Resistance in Breast Cancer

Hanker, A. B., Sudhan, D. R., & Arteaga, C. L. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.009 · Cited by 927

Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α

Campbell, R., Bhat-Nakshatri, P., Patel, N., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 880

Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.

Osborne, C., Bardou, V., Hopp, T. A., Chamness, G., Hilsenbeck, S., Fuqua, S., Wong, J., Allred, D., Clark, G., & Schiff, R. (2003) · Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 831

Treatment of Breast Cancer

Hortobágyi, G. N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810013391407 · Cited by 782

ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer

Jeselsohn, R. M., Buchwalter, G., Angelis, C. D., Brown, M. A., & Schiff, R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.117 · Cited by 744

Cloning of the human estrogen receptor cDNA.

Walter, P., Green, S., Greene, G. L., Krust, A., Bornert, J., Jeltsch, J., Staub, A., Jensen, E. Ø., Scrace, G., & Waterfield, M. D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.23.7889 · Cited by 731

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer

Jeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674

Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.

Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.2920 · Cited by 660

Mechanisms of tamoxifen resistance

Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651

Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts

Li, S., Shen, D., Shao, J., Crowder, R. J., Liu, W., Prat, A., He, X., Liu, S., Hoog, J., Lu, C., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.08.022 · Cited by 637

Estrogen Signaling Multiple Pathways to Impact Gene Transcription

Marino, M., Galluzzo, P., & Ascenzi, P. (2006) · Current Genomics · doi:10.2174/138920206779315737 · Cited by 618

Estrogen receptor alpha and beta in health and disease

Jia, M., Dahlman‐Wright, K., & Gustafsson, J.-Α. (2015) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2015.04.008 · Cited by 573

Risk of endometrial cancer after tamoxifen treatment of breast cancer

van Leeuwen, F. E., van den Belt‐Dusebout, A. W., Leeuwen, F. E. V., Benraadt, J., Diepenhorst, F. W., van Tinteren, H., Coebergh, J. W. W., Kiemeney, L. A. L. M., Gimbrère, C. H. F., Otter, R., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92692-1 · Cited by 566

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer

Bergman, L., Beelen, M. L., Gallee, M. P. W., Hollema, H., Benraadt, J., & van Leeuwen, F. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02677-5 · Cited by 541

Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment

Patel, H., & Bihani, T. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 531

Structure–function relationship of estrogen receptor α and β: Impact on human health

Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 522

The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling

Dauvois, S., White, R., & Parker, M. G. (1993) · Journal of Cell Science · doi:10.1242/jcs.106.4.1377 · Cited by 522

Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship Between Estrogen Receptor, HER-2, and p38 Mitogen-Activated Protein Kinase

Gutierrez, M. C., DETRE, S. I., Johnston, S. R. D., Mohsin, S. K., Shou, J., Allred, D. C., Schiff, R., Osborne, C. K., & Dowsett, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.172 · Cited by 497

Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells.

Ottaviano, Y. L., Issa, J. J., Parl, F. F., Smith, H. S., Baylin, S. B., & Davidson, N. E. (1994) · PubMed · Cited by 481

Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway

Kahlert, S., Nuedling, S., van Eickels, M., Vetter, H., Meyer, R., & Grohé, C. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m910345199 · Cited by 474

Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.

Yang, X., Phillips, D. L., Ferguson, A. T., Nelson, W. G., Herman, J. G., & Davidson, N. E. (2001) · PubMed · Cited by 419

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action

Osborne, C. K., Wakeling, A., & Nicholson, R. I. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601629 · Cited by 414

Aromatase, aromatase inhibitors, and breast cancer

Chumsri, S., Howes, T., Bao, T., Sabnis, G., & Brodie, A. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.02.001 · Cited by 401

FRAP reveals that mobility of oestrogen receptor-α is ligand- and proteasome-dependent

Stenoien, D. L., Patel, K. N., Mancini, M. G., Dutertre, M., Smith, C. L., O’Malley, B. W., & Mancini, M. A. (2000) · Nature Cell Biology · doi:10.1038/35050515 · Cited by 396

Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization.

Fawell, S. E., White, R., Hoare, S., Sydenham, M. A., Pagé, M., & Parker, M. G. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6883 · Cited by 395

Endocrine resistance in breast cancer – An overview and update

Clarke, R. C., Tyson, J. J., & Dixon, J. M. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.09.035 · Cited by 367

Comparison of the Effects of a Pure Steroidal antiestrogen With Those of Tamoxifen in a Model of Human Breast Cancer

Osborne, C. K., Coronado, E. B., Hilsenbeck, S. G., McCue, B. L., Wakeling, A. E., McClelland, R. A., Manning, D. L., & Nicholson, R. I. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.10.746 · Cited by 361

Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation

Fanning, S. W., Mayne, C. G., Dharmarajan, V., Carlson, K. E., Martin, T. A., Novick, S. J., Toy, W., Green, B., Panchamukhi, S., Katzenellenbogen, B. S., et al. (2016) · eLife · doi:10.7554/elife.12792 · Cited by 327

Regulation of Estrogen Rapid Signaling through Arginine Methylation by PRMT1

Romancer, M. L., Treilleux, I., Leconte, N., Robin-Lespinasse, Y., Sentis, S., Bouchekioua‐Bouzaghou, K., Goddard‐Léon, S., Gobert, S., & Corbo, L. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.025 · Cited by 324

First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics

Wu, B., Kulkarni, K. H., Basu, S., Zhang, S., & Hu, M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22568 · Cited by 311

Aromatase Inhibitors in the Treatment and Prevention of Breast Cancer

Goss, P. E., & Strasser, K. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.881 · Cited by 297

Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER)

Hu, J., Hu, B., Wang, M., Xu, F., Miao, B., Yang, C., Wang, M., Liu, Z., Hayes, D. F., Chinnaswamy, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01572 · Cited by 286

An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer.

Zhang, Q., Borg, Å., Wolf, D. M., Oesterreich, S., & Fuqua, S. A. W. (1997) · PubMed · Cited by 286

Pathways to tamoxifen resistance

Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 286

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations

Jeselsohn, R. M., Bergholz, J. S., Pun, M. J., Cornwell, M., Liu, W., Nardone, A., Xiao, T., Li, W., Qiu, X., Buchwalter, G., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.004 · Cited by 281

Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.

Pink, J. J., & Jordan, V. C. (1996) · PubMed · Cited by 276

Tamoxifen, Raloxifene, and the Prevention of Breast Cancer*

Jordan, V. C., & Morrow, M. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0368 · Cited by 260

Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that Demonstrates Robust Activity in Tamoxifen-Resistant Breast Cancer Xenografts

Lai, A. G., Kahraman, M., Govek, S. P., Nagasawa, J. Y., Bonnefous, C., Julien, J., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00054 · Cited by 253

Methylation of estrogen and progesterone receptor gene 5' CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors.

Lapidus, R. G., Ferguson, A. T., Ottaviano, Y. L., Parl, F. F., Smith, H. S., Weitzman, S. A., Baylin, S. B., Issa, J. J., & Davidson, N. E. (1996) · PubMed · Cited by 250

Alpelisib Plus Fulvestrant in PIK3CA -Altered and PIK3CA -Wild-Type Estrogen Receptor–Positive Advanced Breast Cancer

Juric, D., Jankú, F., Rodon, J. A., Burris, H. A., Mayer, I. A., Schüler, M., Seggewiß-Bernhardt, R., Gil-Martín, M., Middleton, M. R., Baselga, J. M., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4475 · Cited by 249

ICI 182,780, a new antioestrogen with clinical potential

Wakeling, A. E., & Bowler, J. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90204-v · Cited by 246

Structural Basis for an Unexpected Mode of SERM-Mediated ER Antagonism

Wu, Y.-L., Yang, X., Ren, Z. M., McDonnell, D. P., Norris, J. D., Willson, T. M., & Greene, G. L. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.04.014 · Cited by 236

Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer

van Kruchten, M., de Vries, E. G. E., Glaudemans, A. W. J. M., van Lanschot, M. C. J., van Faassen, M., Kema, I. P., Brown, M., Schröder, C. P., de Vries, E. F., & Hospers, G. A. P. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0697 · Cited by 229

Efficacy of PI3K inhibitors in advanced breast cancer

Verret, B., Cortes, J., Bachelot, T., Andre, F., & Arnedos, M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz381 · Cited by 221

The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer

Fabian, C. J. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01587.x · Cited by 220

Novel antioestrogens without partial agonist activity

Wakeling, A. E., & Bowler, J. (1988) · Journal of Steroid Biochemistry · doi:10.1016/0022-4731(88)90014-3 · Cited by 214

Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility

Guan, J., Zhou, W. J., Hafner, M. A., Blake, R. A., Chalouni, C. M., Chen, I. P., Bruyn, T. D., Giltnane, J. M., Hartman, S. J., Heidersbach, A. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.026 · Cited by 214

Oxidative Stress and AP-1 Activity in Tamoxifen-Resistant Breast Tumors In Vivo

Schiff, R. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.23.1926 · Cited by 211

Enhanced NFκB and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer

Zhou, Y., Yau, C. S. F., Gray, J. W., Chew, K., Dairkee, S. H., Moore, D. H., Eppenberger, U., Eppenberger‐Castori, S., & Benz, C. C. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-59 · Cited by 208

Tamoxifen Resistance in Breast Cancer

Chang, M.-S. (2012) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2012.20.3.256 · Cited by 205

The Mechanism of ICI 164,384 Antiestrogenieity Involves Rapid Loss of Estrogen Receptor in Uterine Tissue

Gibson, M. K., NEMMERS, L. A., Beckman, W. C., Davis, V. L., Curtis, S. W., & Korach, K. S. (1991) · Endocrinology · doi:10.1210/endo-129-4-2000 · Cited by 198

Measurement of steroid hormone receptors in breast cancer patients on tamoxifen

Encarnaci�n, C. A., Ciocca, D. R., McGuire, W. L., Clark, G. M., Fuqua, S. A. W., & Osborne, C. K. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00665801 · Cited by 194

Estrogen-Induced c-fos Protooncogene Expression in MCF-7 Human Breast Cancer Cells: Role of Estrogen Receptor Sp1 Complex Formation*

Duan, R., Porter, W. W., & Safe, S. H. (1998) · Endocrinology · doi:10.1210/endo.139.4.5870 · Cited by 192

Oral Selective Estrogen Receptor Downregulators (SERDs), a Breakthrough Endocrine Therapy for Breast Cancer

McDonnell, D. P., Wardell, S. E., & Norris, J. D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00760 · Cited by 178

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and ESR1 -Mutant Breast Tumors in Preclinical Models

Weir, H. M., Bradbury, R. H., Lawson, M., Rabow, A. A., Buttar, D., Callis, R. J., Curwen, J., de Almeida, C., Ballard, P. G., Hulse, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2357 · Cited by 178

Fulvestrant (ICI 182,780)-dependent Interacting Proteins Mediate Immobilization and Degradation of Estrogen Receptor-α

Long, X., & Nephew, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510809200 · Cited by 170

Optimization of a Novel Binding Motif to ( E )-3-(3,5-Difluoro-4-((1 R ,3 R )-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1 H -pyrido[3,4- b ]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Savi, C. D., Bradbury, R. H., Rabow, A. A., Norman, R. A., de Almeida, C., Andrews, D. M., Ballard, P. G., Buttar, D., Callis, R. J., Currie, G. S., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00984 · Cited by 169

Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), Has Antitumor Activity in Multiple ER+ Breast Cancer Patient-derived Xenograft Models

Bihani, T., Patel, H., Arlt, H., Tao, N., Jiang, H., Brown, J. L., Purandare, D. M., Hattersley, G., & Garner, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2561 · Cited by 168

RAD1901

Garner, F., Shomali, M., Paquin, D., Lyttle, C. R., & Hattersley, G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000271 · Cited by 162

Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models

Bahreini, A., Li, Z., Wang, P., Levine, K. M., Tasdemir, N., Cao, L., Weir, H. M., Puhalla, S. L., Davidson, N. E., Stern, A. M., et al. (2017) · Breast Cancer Research · doi:10.1186/s13058-017-0851-4 · Cited by 156

Biology and mode of action of pure antioestrogens.

Wakeling, A. E., & Bowler, J. (1988) · PubMed · doi:10.1016/0022-4731(88)90086-6 · Cited by 150

3-[4-(1,2-Diphenylbut-1-enyl)phenyl]acrylic Acid: A Non-Steroidal Estrogen with Functional Selectivity for Bone over Uterus in Rats

Willson, T. M., Henke, B. R., Momtahen, T. M., Charifson, P. S., Batchelor, K. W., Lubahn, D. B., Moore, L. B., Oliver, B. B., Sauls, H. R., Triantafillou, J. A., et al. (1994) · Journal of Medicinal Chemistry · doi:10.1021/jm00037a002 · Cited by 146

Endocrine treatment in breast cancer: Cure, resistance and beyond

Tryfonidis, K., Zardavas, D., Katzenellenbogen, B. S., & Piccart, M. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.008 · Cited by 145

Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer

Tria, G. S., Abrams, T. J., Baird, J., Burks, H. E., Firestone, B., Gaither, L. A., Hamann, L. G., He, G., Kirby, C. A., Kim, S., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01682 · Cited by 134

Adverse Effect of Adjuvant Tamoxifen in Premenopausal Breast Cancer with Cyclin D1 Gene Amplification

Jirström, K., Stendahl, M., Rydén, L., Kronblad, Å., Bendahl, P.-O., Stål, O., Landberg, G., & Groups., T. S. S. A. S. S. B. C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0746 · Cited by 133

Action of ?pure? antiestrogens in inhibiting estrogen receptor action

Parker, M. G. (1993) · Breast Cancer Research and Treatment · doi:10.1007/bf00689686 · Cited by 131

The History and Mechanism of Action of Fulvestrant

Carlson, R. W. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.s.008 · Cited by 131

Studies on the mechanism of action of the nonsteroidal antioestrogen tamoxifen (I.C.I. 46,474) in the rat

Jordan, V. C., DIX, C. J., Rowsby, L., & Prestwich, G. (1977) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(77)90066-1 · Cited by 129

Understanding the genotoxicity of tamoxifen?

Phillips, D. H. (2001) · Carcinogenesis · doi:10.1093/carcin/22.6.839 · Cited by 125

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

Joseph, J. D., Darimont, B. D., Zhou, W. J., Arrazate, A., Young, A. E., Ingalla, E., Walter, K., Blake, R. A., Nonomiya, J., Guan, Z., et al. (2016) · eLife · doi:10.7554/elife.15828 · Cited by 123

New biospecific adsorbents for the purification of estradiol receptor.

Bucourt, R., Vignau, M., & TORELLI, V. (1978) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34385-5 · Cited by 121

Evaluation of the pharmacological activities of RAD1901, a selective estrogen receptor degrader

Wardell, S. E., Nelson, E. R., Chao, C., Alley, H. M., & McDonnell, D. P. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0287 · Cited by 118

Estrogen Receptor-α Hinge-Region Lysines 302 and 303 Regulate Receptor Degradation by the Proteasome

Berry, N. B., Fan, M., & Nephew, K. P. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0449 · Cited by 116

RU 58 668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice

Velde, P. V. D., Nique, F., Bouchoux, F., Brémaud, J., HAMEAU, M., Lucas, D., Moratille, C., Viet, S., Philibert, D., & Teutsch, G. (1994) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(94)90144-9 · Cited by 115

Acquired resistance to aromatase inhibitors: where we stand!

Augusto, T. V., Correia‐da‐Silva, G., Rodrigues, C., Teixeira, N. A. A., & Amaral, C. (2018) · Endocrine Related Cancer · doi:10.1530/erc-17-0425 · Cited by 114

Biological mechanisms and clinical implications of endocrine resistance in breast cancer.

Giuliano, M., Schiff, R., Osborne, C., & Trivedi, M. V. (2011) · Breast · doi:10.1016/s0960-9776(11)70293-4 · Cited by 111

Novel Mechanisms of Resistance to Endocrine Therapy: Genomic and Nongenomic Considerations

Gururaj, A. E., Rayala, S. K., Vadlamudi, R. K., & Kumar, R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2110 · Cited by 109

Requirements for estrogen receptor α membrane localization and function

Evinger, A. J., & Levin, E. (2005) · Steroids · doi:10.1016/j.steroids.2005.02.015 · Cited by 108

Aromatase inhibitors and their application in breast cancer treatment⋆

Brodie, A. M. H. (2000) · Steroids · doi:10.1016/s0039-128x(99)00104-x · Cited by 106

Nuclear Receptors, Coregulators, Ligands, and Selective Receptor Modulators

McKenna, N. J., & O’Malley, B. W. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03997.x · Cited by 96

Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

Rudas, M., Lehnert, M., Huynh, A. T., Jakesz, R., Singer, C., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4122 · Cited by 93

Overexpression, Purification, and Crystal Structure of Native ERα LBD

Eiler, S., Gangloff, M., Duclaud, S., Moras, D., & Ruff, M. (2001) · Protein Expression and Purification · doi:10.1006/prep.2001.1409 · Cited by 92

Discovery of 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid (SAR439859), a Potent and Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen-Receptor-Positive Breast Cancer

El‐Ahmad, Y., Tabart, M., Halley, F., Certal, V., Thompson, F., Filoche-Rommé, B., Gruss-Leleu, F., Muller, C., Brollo, M., Fabien, L., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01293 · Cited by 92

FDA Drug Approval Summaries: Fulvestrant

Bross, P. F., Cohen, M. H., Williams, G. A., & Pazdur, R. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-477 · Cited by 91

Estrogen Receptors in Target Tissues

Jensen, E. V., Jacobson, H. I., Flesher, J. W., Saha, N., Gupta, G. N., Smith, S. B., COLUCCI, V., SHIPLACOFF, D., Neumann, H. G., DeSombre, E. R., et al. (1966) · Elsevier eBooks · doi:10.1016/b978-1-4832-2903-4.50009-x · Cited by 90

Estrogen Receptor Modulators: Identification and Structure−Activity Relationships of Potent ERα-Selective Tetrahydroisoquinoline Ligands

Renaud, J., Bischoff, S. F., Buhl, T., Floersheim, P., Fournier, B., Halleux, C. M., Kallen, J. A., Keller, H., Schlaeppi, J.-M., & Stark, W. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030086h · Cited by 89

Use of pure antioestrogens to elucidate the mode of action of oestrogens

Wakeling, A. E. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)00528-t · Cited by 88

ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective

Saxena, R., & Dwivedi, A. (2010) · Medicinal Research Reviews · doi:10.1002/med.20209 · Cited by 88

Characterization of New Estrogen Receptor Destabilizing Compounds: Effects on Estrogen-Sensitive and Tamoxifen-Resistant Breast Cancer

Hoffmann, J., Bohlmann, R., Heinrich, N., Hofmeister, H., Kroll, J., Künzer, H., Lichtner, R. B., Nishino, Y., Parczyk, K., Sauer, G., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh022 · Cited by 87

Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD)

Liu, J., Zheng, S., Akerstrom, V. L., Yuan, C., Ma, Y., Zhong, Q., Zhang, C., Zhang, Q., Guo, S., Ma, P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00753 · Cited by 86

Responses to Pure Antiestrogens (ICI 164384, ICI182780) in Estrogen‐Sensitive and‐Resistant Experimental and Clinical Breast Cancera

Nicholson, R. I., Gee, J. M. W., Manning, D. L., Wakeling, A. E., Montano, M. M., & Katzenellenbogen, B. S. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb31376.x · Cited by 84

Novel Selective Estrogen Receptor Downregulators (SERDs) Developed against Treatment-Resistant Breast Cancer

Xiong, R., Zhao, J., Gutgesell, L. M., Wang, Y., Lee, S., Karumudi, B., Zhao, H., Lu, Y., Tonetti, D. A., & Thatcher, G. R. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01355 · Cited by 83

The development of endocrine therapy for women with breast cancer

Sainsbury, R. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.07.006 · Cited by 79

Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors

Patel, H., Tao, N., Lee, K.-M., Huerta-Rosario, M., Arlt, H., Mullarkey, T. L., Troy, S. M., Arteaga, C. L., & Bihani, T. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1230-0 · Cited by 78

Maximizing ER-α Degradation Maximizes Activity in a Tamoxifen-Resistant Breast Cancer Model: Identification of GDC-0927

Kahraman, M., Govek, S. P., Nagasawa, J. Y., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Liu, N., Lee, K., Aparicio, A. M., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00414 · Cited by 78

A Good Drug Made Better: The Fulvestrant Dose-Response Story

Robertson, J. F. R., Lindemann, J. P. O., Garnett, S., Anderson, E., Nicholson, R. I., Kuter, I., & Gee, J. M. W. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2014.06.005 · Cited by 72

The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance

Nardone, A., Weir, H. M., Delpuech, O., Brown, H., Angelis, C. D., Cataldo, M. L., Fu, X., Shea, M. J., Mitchell, T., Veeraraghavan, J., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0354-9 · Cited by 68

Selective Estrogen Receptor Modulators with Conformationally Restricted Side Chains. Synthesis and Structure−Activity Relationship of ERα-Selective Tetrahydroisoquinoline Ligands

Renaud, J., Bischoff, S. F., Buhl, T., Floersheim, P., Fournier, B., Geiser, M., Halleux, C. M., Kallen, J. A., Keller, H., & Ramage, P. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040858p · Cited by 67

Full antagonism of the estrogen receptor without a prototypical ligand side chain

Srinivasan, S., Nwachukwu, J. C., Bruno, N. E., Dharmarajan, V., Goswami, D., Kastrati, I., Novick, S. J., Nowak, J., Cavett, V. J., Zhou, H., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2236 · Cited by 66

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

Paoletti, C., Schiavon, G., Dolce, E. M., Darga, E. P., Carr, T. H., Geradts, J., Hoch, M., Klinowska, T. C. M., Lindemann, J. P. O., Marshall, G. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1569 · Cited by 66

Specific stereochemistry of OP-1074 disrupts estrogen receptor alpha helix 12 and confers pure antiestrogenic activity

Fanning, S. W., Hodges-Gallagher, L., Myles, D. C., Sun, R., Fowler, C. E., Plant, I. N., Green, B. D., Harmon, C. L., Greene, G. L., & Kushner, P. J. (2018) · Nature Communications · doi:10.1038/s41467-018-04413-3 · Cited by 64

Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer

Shagufta, Ahmad, I., Mathew, S., & Rahman, S. (2020) · RSC Medicinal Chemistry · doi:10.1039/c9md00570f · Cited by 64

Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer

Xiong, R., Patel, H., Gutgesell, L. M., Zhao, J., Delgado-Rivera, L., Pham, T. D., Zhao, H., Carlson, K. E., Martin, T. A., Katzenellenbogen, J. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01276 · Cited by 63

Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers

Fumagalli, D., Wilson, T. R., Salgado, R., Lu, X., Yu, J., O'Brien, C. L., Walter, K., Huw, L., Criscitiello, C., Laïos, I., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw286 · Cited by 61

New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons

Wang, L., Guillen, V. S., Sharma, N., Flessa, K., Min, J., Carlson, K. E., Toy, W., Braqi, S., Katzenellenbogen, B. S., Katzenellenbogen, J. A., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00106 · Cited by 61

Oestrogen Receptors and Selective Oestrogen Receptor Modulators: Molecular and Cellular Pharmacology

Nilsson, S. V., & Koehler, K. F. (2005) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2005.pto960103.x · Cited by 57

Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)

Kieser, K. J., Kim, D. W., Carlson, K. E., Katzenellenbogen, B. S., & Katzenellenbogen, J. A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100047k · Cited by 56

Inactivation of the Pure Antiestrogen Fulvestrant and Other Synthetic Estrogen Molecules by UDP-Glucuronosyltransferase 1A Enzymes Expressed in Breast Tissue

Chouinard, S., Tessier, M., Vernouillet, G., Gauthier, S., Labrie, F., Barbier, O., & Bélanger, A. (2005) · Molecular Pharmacology · doi:10.1124/mol.105.015891 · Cited by 54

Optimization of an indazole series of selective estrogen receptor degraders: Tumor regression in a tamoxifen-resistant breast cancer xenograft

Govek, S. P., Nagasawa, J. Y., Douglas, K. L., Lai, A. G., Kahraman, M., Bonnefous, C., Aparicio, A. M., Darimont, B. D., Grillot, K. L., Joseph, J. D., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.09.074 · Cited by 50

Development of New Estrogen Receptor-Targeting Therapeutic Agents for Tamoxifen-Resistant Breast Cancer

Jiang, Q., Zheng, S., & Wang, G. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.63 · Cited by 48

Discovery of an Acrylic Acid Based Tetrahydroisoquinoline as an Orally Bioavailable Selective Estrogen Receptor Degrader for ERα+ Breast Cancer

Burks, H. E., Abrams, T. J., Kirby, C. A., Baird, J., Fekete, A., Hamann, L. G., Kim, S., Lombardo, F., Loo, A. T., Lubicka, D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01468 · Cited by 47

Lead Optimization of Benzoxepin-Type Selective Estrogen Receptor (ER) Modulators and Downregulators with Subtype-Specific ERα and ERβ Activity

O’Boyle, N. M., Barrett, I., Greene, L. M., Carr, M. J., Fayne, D., Twamley, B., Knox, A. J. S., Keely, N. O., Zisterer, D. M., & Meegan, M. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01917 · Cited by 47

Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)

Li, Y., Zhang, S., Zhang, J., Hu, Z., Yuan, X., Huang, J., Dong, C., Huang, S., & Zhou, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.03.058 · Cited by 47

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer

Andreano, K. J., Wardell, S. E., Baker, J. G., Desautels, T. K., Baldi, R. M., Chao, C., Heetderks, K. A., Bae, Y., Xiong, R., Tonetti, D. A., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05575-9 · Cited by 47

Modulation of nuclear receptor activity by the F domain

Patel, S. R., & Skafar, D. F. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.009 · Cited by 46

Investigation of (E)-3-[4-(2-Oxo-3-aryl-chromen-4-yl)oxyphenyl]acrylic Acids as Oral Selective Estrogen Receptor Down-Regulators

Degorce, S. L., Bailey, A., Callis, R. J., Savi, C. D., Ducray, R., Lamont, G. M., MacFaul, P. A., Maudet, M., Martin, S. W., Morgentin, R., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00066 · Cited by 46

In vitro and in vivo biologic evaluation of long‐circulating biodegradable drug carriers loaded with the pure antiestrogen RU 58668

Ameller, T., Marsaud, V., Legrand, P., Gref, R., & Renoir, J. (2003) · International Journal of Cancer · doi:10.1002/ijc.11248 · Cited by 46

Design and Synthesis of Basic Selective Estrogen Receptor Degraders for Endocrine Therapy Resistant Breast Cancer

Lu, Y., Gutgesell, L. M., Xiong, R., Zhao, J., Li, Y., Rosales, C. I., Hollas, M. A. R., Shen, Z., Gordon-Blake, J. M., Dye, K., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01580 · Cited by 46

Identification of an Orally Bioavailable Chromene-Based Selective Estrogen Receptor Degrader (SERD) That Demonstrates Robust Activity in a Model of Tamoxifen-Resistant Breast Cancer

Nagasawa, J. Y., Govek, S. P., Kahraman, M., Lai, A. G., Bonnefous, C., Douglas, K. L., Sensintaffar, J., Lu, N., Lee, K., Aparicio, A. M., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00921 · Cited by 44

Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat

Scott, J. S., Bailey, A., Davies, R. D. M., Degorce, S. L., MacFaul, P. A., Gingell, H., Moss, T., Norman, R. A., Pink, J. H., Rabow, A. A., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00413 · Cited by 43

Ligand-Induced Estrogen Receptor α Degradation by the Proteasome: New Actors?

Calligé, M., & Richard‐Foy, H. (2006) · Nuclear Receptor Signaling · doi:10.1621/nrs.04004 · Cited by 43

Rational Design of a Boron-Modified Triphenylethylene (GLL398) as an Oral Selective Estrogen Receptor Downregulator

Liu, J., Zheng, S., Guo, S., Zhang, C., Zhong, Q., Zhang, Q., Ma, P., Skripnikova, E., Bratton, M. R., Wiese, T. E., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00410 · Cited by 42

Boronic prodrug of 4-hydroxytamoxifen is more efficacious than tamoxifen with enhanced bioavailability independent of CYP2D6 status

Zhong, Q., Zhang, C., Zhang, Q., Miele, L., Zheng, S., & Wang, G. (2015) · BMC Cancer · doi:10.1186/s12885-015-1621-2 · Cited by 42

Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction Profiling

Hoekstra, W. J., Patel, H. S., Liang, X., Blanc, J.-B. E., Heyer, D. O., Willson, T. M., Iannone, M. A., Kadwell, S. H., Miller, L. A., Pearce, K. H., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm040154f · Cited by 42

Tricyclic Indazoles—A Novel Class of Selective Estrogen Receptor Degrader Antagonists

Scott, J. S., Bailey, A., Buttar, D., Carbajo, R. J., Curwen, J., Davey, P. R. J., Davies, R. D. M., Degorce, S. L., Donald, C. S., Gangl, E. T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01837 · Cited by 41

Purification of estradiol receptor by affinity chromatography. Representative experiments

Truong, H., Geynet, C., Millet, C., Soulignac, O., Bucourt, R., VIGNAU, M., TORELLI, V., & Baulieu, É.-É. (1973) · FEBS Letters · doi:10.1016/0014-5793(73)80306-0 · Cited by 40

Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure–activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides

Zhu, M., Zhang, C., Nwachukwu, J. C., Srinivasan, S., Cavett, V. J., Zheng, Y., Carlson, K. E., Dong, C., Katzenellenbogen, J. A., Nettles, K. W., et al. (2012) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob26531a · Cited by 38

ERα-associated protein networks

Schultz-Norton, J. R., Ziegler, Y., & Nardulli, A. M. (2011) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2010.11.005 · Cited by 38

Boronic prodrug of endoxifen as an effective hormone therapy for breast cancer

Zhang, C., Zhong, Q., Zhang, Q., Zheng, S., Miele, L., & Wang, G. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3461-9 · Cited by 38

Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells

Min, J., Guillen, V. S., Sharma, A., Zhao, Y., Ziegler, Y., Gong, P., Mayne, C. G., Srinivasan, S., Kim, S. H., Carlson, K. E., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00585 · Cited by 35

Anti‐breast cancer potential of SS5020, a novel benzopyran antiestrogen

Suzuki, N., Liu, X., Laxmi, Y. R. S., Okamoto, K., Kim, H. J., Zhang, G., Chen, J. J., Okamoto, Y., & Shibutani, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25659 · Cited by 35

Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer

Busonero, C., Leone, S., Bartoloni, S., & Acconcia, F. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.10.020 · Cited by 34

Antiestrogenic activity of two 11β-estradiol derivatives on MCF-7 breast cancer cells

Jin, L. (1995) · Steroids · doi:10.1016/0039-128x(95)00079-6 · Cited by 34

Pure antiestrogen RU 58668—loaded nanospheres: morphology, cell activity and toxicity studies

Ameller, T., Marsaud, V., Legrand, P., Gref, R., & Renoir, J. (2003) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2003.11.002 · Cited by 34

Discovery of GNE-149 as a Full Antagonist and Efficient Degrader of Estrogen Receptor alpha for ER+ Breast Cancer

Liang, J., Blake, R. A., Chang, J. H., Friedman, L. S., Goodacre, S. C., Hartman, S. J., Ingalla, E., Kiefer, J. R., Kleinheinz, T., Labadie, S. S., et al. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00224 · Cited by 33

RU 58668: Further in vitro and in vivo pharmacological data related to its antitumoral activity

Velde, P. V. D., Nique, F., Planchon, P., Prevost, G. P., Brémaud, J., HAMEAU, M., Magnien, V., Philibert, D., & Teutsch, G. (1996) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(96)00140-9 · Cited by 33

Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain

Blizzard, T. A., DiNinno, F. P., Chen, H. Y., Kim, S., Wu, J. Y., CHAN, W. W.-S., Birzin, E. T., Yang, Y. T., Pai, L.-Y., Hayes, E. C., et al. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.05.089 · Cited by 33

Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators

Shoda, T., Kato, M., Harada, R., Fujisato, T., Okuhira, K., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.05.002 · Cited by 32

Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator

Shoda, T., Okuhira, K., Kato, M., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.11.078 · Cited by 30

Both N- and C-terminal transactivation functions of DNA-bound ERalpha are blocked by a novel synthetic estrogen ligand.

Yamamoto, Y., Wada, O., Takada, I., Yogiashi, Y., Shibata, J., Yanagisawa, J., Kitazato, K., & Kato, S. (2003) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2003.10.178 · Cited by 30

Faslodex (ICI 182780)

Howell, A. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00241-0 · Cited by 30

A Screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs)

Callis, R. J., Rabow, A. A., Tonge, M. E., Bradbury, R. H., Challinor, M., Roberts, K., Jones, K. L., & Walker, G. E. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115580298 · Cited by 29

The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor

Casa, A. J., Hochbaum, D., Sreekumar, S., Oesterreich, S., & Lee, A. V. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.08.007 · Cited by 28

Multiple mechanisms of estrogen receptor gene repression contribute to ER-negative breast cancer

Parl, F. F. (2003) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500201 · Cited by 28

Partial antagonism between steroidal and nonsteroidal antiestrogens in human breast cancer cell lines.

Müller, V., Jensen, E. V., & Knabbe, C. (1998) · PubMed · Cited by 24

Selective Estrogen Receptor Modulator Medicinal Chemistry At Merck. A Review

Blizzard, T. A. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608784535066 · Cited by 23

FULVESTRANT: A REVIEW OF ITS DEVELOPMENT, PRE‐CLINICAL AND CLINICAL DATA

Wardley, A. M. (2002) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2002.tb11261.x · Cited by 23

Synthesis and structure–activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution

Gauthier, S., Cloutier, J., Dory, Y. L., Favre, A., Mailhot, J., Ouellet, C., Schwerdtfeger, A., Mérand, Y., Martel, C., Simard, J., et al. (2005) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756360500043448 · Cited by 21

Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator

Shoda, T., Kato, M., Fujisato, T., Misawa, T., Demizu, Y., Inoue, H., Naito, M., & Kurihara, M. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.04.068 · Cited by 20

Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity

Hu, Z., Li, Y., Xie, B., Ning, W., Yuan, X., Huang, Y., Zhao, C., Huang, J., Dong, C., & Zhou, H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111605 · Cited by 20

Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels

Yoneya (2009) · Oncology Reports · doi:10.3892/or_00000280 · Cited by 17

TAS-108: A Novel Steroidal Antiestrogen

Buzdar, A. U. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.906s.11.2 · Cited by 17

Building Bridges in a Series of Estrogen Receptor Degraders: An Application of Metathesis in Medicinal Chemistry

Scott, J. S., Breed, J., Carbajo, R. J., Davey, P. R. J., Greenwood, R. D. R., Huynh, H. K., Klinowska, T. C. M., Morrow, C. J., Moss, T. A., Polański, R., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00370 · Cited by 16

Anti‐breast cancer potential of SS1020, a novel antiestrogen lacking estrogenic and genotoxic actions

Laxmi, Y. R. S., Liu, X., Suzuki, N., Kim, S. Y., Okamoto, K., Kim, H. J., Zhang, G., Chen, J. J., Okamoto, Y., & Shibutani, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25167 · Cited by 14

Discovery of a C-8 hydroxychromene as a potent degrader of estrogen receptor alpha with improved rat oral exposure over GDC-0927

Labadie, S. S., Li, J., Blake, R. A., Chang, J. H., Goodacre, S. C., Hartman, S. J., Liang, W., Kiefer, J. R., Kleinheinz, T., Lai, T., et al. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.07.013 · Cited by 14

Parameters influencing the purification of calf uterus estrogen ‘receptor’ by affinity chromatography

Truong, H., & Baulieu, É.-É. (1974) · FEBS Letters · doi:10.1016/0014-5793(74)80397-2 · Cited by 12

Identification of a novel, orally bioavailable estrogen receptor downregulator

Yoneya, T., Taniguchi, K., Tsunenari, T., Saito, H., Kanbe, Y., Morikawa, K., & Yamada‐Okabe, H. (2005) · Anti-Cancer Drugs · doi:10.1097/01.cad.0000171515.27439.de · Cited by 10

Randomized phase II study of three doses of oral TAS ‐108 in postmenopausal patients with metastatic breast cancer

Inaji, H., Iwata, H., Nakayama, T., Yamamoto, N., Sato, Y., Tokuda, Y., Aogi, K., Saji, S., Watanabe, K., Saito, T., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02354.x · Cited by 8

Randomized double‐blind phase 2 trial of 3 doses of TAS‐108 in patients with advanced or metastatic postmenopausal breast cancer

Buzdar, A. U., Vogel, C., Schwartzberg, L. S., Garin, A. M., Perez, A., Ingle, J. N., Houghton, M., Zergebel, C., & Kimball, B. (2011) · Cancer · doi:10.1002/cncr.26419 · Cited by 6

Overcoming Cancer Drug Resistance Utilizing PROTAC Technology

Burke, M. R., Smith, A. R., & Zheng, G. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.872729 · Cited by 129

Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges

Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 117

Targeting Breast Cancer: An Overlook on Current Strategies

Iacopetta, D., Ceramella, J., Baldino, N., Sinicropi, M., & Catalano, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043643 · Cited by 88

Accelerating drug development in breast cancer: New frontiers for ER inhibition

Ferraro, E., Walsh, E. M., Tao, J. J., Chandarlapaty, S., & Jhaveri, K. L. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102432 · Cited by 57

Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity

Chen, Z., Hu, B., Rej, R. K., Wu, D., Acharyya, R. K., Wang, M., Xu, T., Lü, J., Metwally, H., Wang, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01186 · Cited by 54

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective

Hernándo, C., Ortega-Morillo, B., Tapia, M., Moragón, S., Martínez, M. T., Eroles, P., Garrido‐Cano, I., Adam‐Artigues, A., Lluch, A. M., Bermejo, B., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22157812 · Cited by 147

Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status

Downton, T. D., Zhou, F. H., Segara, D., Jeselsohn, R. M., & Lim, E. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s380925 · Cited by 72

Pharmacological insights on novel oral selective estrogen receptor degraders in breast cancer

Guglielmi, G., Re, M. D., Gol, L. S., Bengala, C., Danesi, R., & Fogli, S. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176424 · Cited by 40

Oral selective estrogen receptor degraders (SERDs): The new emperors in breast cancer clinical practice?

Ferro, A., Generali, D., Caffo, O., Caldara, A., Lisi, D. D., Dipasquale, M., Lorenzi, M., Monteverdi, S., Fedele, P., & Ciribilli, Y. (2023) · Seminars in Oncology · doi:10.1053/j.seminoncol.2023.08.002 · Cited by 9

Selective Estrogen Receptor Degraders (SERDs)

Taylor, M., Kahn, A. M., & Foldi, J. (2024) · Current Breast Cancer Reports · doi:10.1007/s12609-024-00563-0 · Cited by 3